initi coverag
reset base pipelin capit alloc
sourc upsid initi buy
initi share buy rate pt base
ep stock trade follow
choppi result believ recent under-perform share give investor
attract buy opportun medic deliveri headwind next
period bake expect stabl growth
busi new product could help bigger one consensu
estim impli growth xfx forecast
includ busi develop could give upsid
pipelin underestim new product help bigger one
hand new launch infus pump prismax kaguya new molecul
help bigger pipelin event think shift growth
analysi point care periton dialysi suggest paradigm shift therapi
deliveri could significantli expand revenu base reduc cost renal
year histori guid pharma launch could come us base
pipelin schedul forecast organ growth tick
beyond base product flow
mani larg med-tech compani de-lever larg deal balanc sheet
differenti asset manag brought ceo almeida
strong track record creat valu deal mostli growth margin
accret tuck-in slightli larger deal covidien cash
debt cash gener expect next three year plenti
dri powder deal buy-back recent increas repo author
could buy back share base today without lever
valuat pe discount recent
trade ep pt assum modest multipl expans
air clear around recent issu pipelin come view stretch
consid recent peak
trade data key metric
compani account thomson reuter ub estim metric mark ub analyst adjust appli valuat base averag share price year base
share price estimate
report prepar ub secur llc analyst certif requir disclosur begin
page ub seek busi compani cover research report result investor
awar firm may conflict interest could affect object report investor consid
report singl factor make invest decis
ub research thesi map guid think report
 organ grow top line sustain
ye consensu estim impli growth xfx follow bumpi
expect lower issu temporari product launch
shift growth forecast includ busi develop
could give upsid
 balanc sheet discount current level
current capac estim could buy back share base deal could
deliv msd accret year one look anoth way use
capac today purchas larg deal high teen ebitda multipl could add bp
growth math multipl equal today
 overachiev margin target
possibl upsid pipelin busi develop given track record
expect portfolio mix cost plan rang look reason us model high end
versu consensu
buy rate base view share current bake much fear around
revenu growth soft due issu medic deliveri number rebas think
move past issu drive higher growth model reach
growth base case think drive re-rat higher
base busi rel stabl consid product use necessari procedur
tie long term contract volum price commit analys new product
opportun includ pharma launch point care periton dialysi next-gener
pump bridg growth also under-lev number plan assum
bd could lead upsid growth/margin target multipl
trade ep recent peak consensu forecast call
organ growth ep growth period
upsid downsid
compani descript baxter intern provid broad portfolio essenti healthcar product across portfolio
includ acut chronic dialysi therapi steril intraven iv
initi coverag novemb
new product differenti growth invest
expect shift growth period
time dramat grow margin
mix cost effort expans
expect year
balanc sheet lot dri powder
manag team skill deploy
bump put stock sale discount
pe rel
average rel
sourc exhibit compani data ub research
initi coverag novemb
order see whether thesi play here well track
next six month beyond
late point approv
continu see limit cyclo competit
despit entrant us market guid
cyclo sale expect mm
upsid conserv model next year
con midpoint due fx underli in-lin
typic report result late jan earli feb
expect revenu in-lin forecast
organ growth given recent headwind slight ep
beat higher margin think
underli guidanc bracket street
revenu midpoint could con given recent
strength dollar
growth
call sever issu medic deliveri
busi custom order product
destock anticip forecast
expect larg volum parenter reach equilibrium
small volum nutrit harder get
back iv solut also tough comp
built pharma busi acquisit
partnership new molecul launch
clari busi deliv
us market model growth clari
point share gain annual
market share posit pump space
behind bd/carfus hold share next-
gen pump abl meet hospit need
one pump put even foot
carefus gain point share gain
year expect new system acceler share
shipment reduc
leader periton dialysi launch
point care product
reconstitut home rather ship larg
volum solut patient hous could lower
barrier use product reduc cost
shipment could reduc
initi coverag novemb
point pd
compani report ub estim
new molecul us peak sale mm
 next year
 molecul pipelin
augment portfolio expand indic current product
 pressur
mm new product sale
initi coverag novemb
 organ grow top line
ye time organ growth growth
touch quarter move past volatil around
hurrican suppli issu launch new product
expect growth acceler level larger catalyst
includ next gen pump pharma launch kaguya point care
pd system abil drive growth also
under-lev long rang plan assum busi develop
manag activ bd front expect deal
growth margin accret base plan
detail product pipelin analysi point sustain growth
baselin reset expect still
expect forward growth rate line long rang plan new base
sale necessari procedur much
busi tie multi-year contract stand volum price
commit give visibl baselin level growth beyond
differenti invest pipelin start produc result new
product cadenc growth pick see benefit
version pump prismax kaguya pharma launch new
product cadenc inflect next gen pump pharma
launch launch point care pd late period
consensu estim impli growth xfx follow
bumpi expect lower growth
growth call oper growth
new product geograph expans
new product revenu stem priorit
new pump point-of-car drug launch
point periton dialysi
initi coverag novemb
illustr think headwind mostli temporari
downward re-rat given investor opportun buy stock
discount busi reset go forward expect
grow rate in-lin longer term forecast see
miss expect given issu four busi larg volum
parenter lvp small volum parenter svp nutrit iv bag
essenti think lvp tough comp gain
busi back volum tie long term contract
commit svp take block tackl includ market
effort full suppli win back share comp eas busi
mid-teen nutrit dollar may come back invest
studi show benefit nutrit could help smallest
issu iv tough comp given restock flu
said account headwind growth
medic deliveri recov time
expect busi rel stabl potenti
bigger acceler product includ prismax molecul
launch pharma kaguya japan version integr pump
includ larger launch like next gener pump pharma
launch us close launch demand pd
figur outlook busi
deconstruct issu time forecast chang behavior
recent volatil purchas behavior larg volum parenter lvp led
disappoint organ growth despit end
market demand lvp remain consist low singl digit
relat time lvp grow distributor
restock hurrican inventori came channel
lead lower sale growth period abl
forecast dynam well sinc made chang personnel
process around forecast item
flip-flop spook investor ytd lvp grown vs
market us lrp
modest expect busi lsd growth versu dd growth
initi coverag novemb
histor time impact much busi tie long
term volum relat contract specif purchas level built give
better abil predict level sale busi look forward
svp busi mini-bag saw chang behavior hospit
follow suppli disrupt post hurrican without mini-bag
reconstitut drug hospit move iv push administr move
competit product expect regain busi could
take time given need show hospit adequ suppli
product support volum time bag
optim way deliv med case offer superior safeti eas
administr busi declin mid-
teen follow impact set busi also
y/i
nutrit seen market contract result hurrican relat
suppli constraint well provid either delay start parenter
nutrit decreas dosag also seen shift outsourc
nutrit compound center move competit product unlik
regain lost sale due market contract
rebas busi expect resum us market growth lsd
come quarter smallest issu us continu
see steadi growth intern us nutrit busi
final iv time issu custom rush acquir avail
iv solut first five month year given industri wide suppli
challeng strong flu season forecast built elev run
rate contempl level destock constraint
growth call oper growth
new product geograph expans
may analyst day laid plan grow top line xfx
compound-annual-growth-rate grow
embed growth competit associ
cyclophosphamid brevibloc take adjust averag north
compound growth split oper growth new
products/geograph expans expect grow bp oper
includ bp competit
market current grow includ growth renal
revenu medic deliveri
clinic nutrit advanc surgeri
acut therapi compani growth outlook call grow
market rate slightli market renal
medic deliveri clinic nutrit advanc surgeri acut therapi
pharma growth market assum competit cyclo
brevibloc invest focus improv weight averag
market growth rate heavi focu gross margin help obtain
initi coverag novemb
figur bridg organ growth
new product revenu stem priorit
past year focus optim work
pipelin categor three area novel product life-cycle
manag geograph expans consolid group
reduc mainten overhead associ part
organ creat effici way deliv innov part
initi exit certain site downsiz other tri strike
balanc site around globe stay close custom
reduc complex network around world
new manag team pace new product introduct
increas look forward expect revenu contribut new
product acceler new product expect contribut
revenu grow
forecast includ risk-adjust new product order
sever hundr million dollar forecast period account regulatori
execut risk highlight risk
adjust get haircut midpoint
adjust haircut de-risk new technolog one yet
approv payoff away larger discount
figur new product contribut expect increas
initi coverag novemb
plan enter adjac acquisit fund organ growth use
balanc sheet includ invest strateg growth area
includ clinic evid gener educ awar target
market invest note may analyst day sever
product disclos competit reason addit project
baxter ventur capit group univers partnership
new pump point-of-car drug launch
product launch includ next gener pump point-of-car
system pd number drug
gener pump remind market leader infus
pump sigma spectrum sigma platform includ impress drug
librari help reduc risk medic error particip
posit us market infus system
medic deliveri busi roughli iv
therapi solut mini bag infus system pump set
connector busi go hand-in hand sale pump help
pull set connector solut well estim
portfolio innov busi add new product revenu
includ new version spectrum iq new pump platform
evo iq platform intern market
pump advanc includ autom comprehens drug
librari still death per year relat deliveri
medic prevent advers event per year associ
inject medic new pump aim address issu
sigma spectrum version iq import product
receiv approv may launch product
us canada bring bi-direct integr auto-
program auto-document industry-lead workflow pump
also barcod reader differenti featur continu build drug
librari capabl improv safeti profil iq also integr locat
technolog help hospit manag asset maxim util
initi coverag novemb
believ iq best pump market ad auto-program fill
gap rel competitor
term dollar opportun launch intern
enter patient control analgesia pca market larger given
area particip today plan launch larg
volum infus pump intern market includ initi target australia
new zealand uk ireland give abil address
market offer year evo iq includ larg volum
syring pump drug librari wireless gateway compet global
market evo iq syring expect launch give full
portfolio ou think modestli de-featur lower price point
pump ou market stage base colleagu
pump market ou grow potenti share
gain beyond
demonstr prototyp next gener global infus
pump may analyst day expect launch
includ best technolog spectrum platform idea behind
new pump one solut meet hospit critic infus
pump need replac larg volum pump syring pump pain
manag devic integr back end stage
bdx/carefus alari three combin clearli
benefit market share us continu gain
share anoth share gain expect year
design allow integr easili devic patient monitor
address technolog obsolesc wireless softwar updat notabl
pca market new repres increment opportun
hardwar includ set
initi coverag novemb
point periton dialysi
particip global renal market grow
includ extracorpor hemodialysi hd market grow
smaller periton dialysi pd market grow posit
hd market share posit pd renal
busi pd includ amia us claria row cycler solut
renal largest busi compris group revenu
next sever year expect number key launches/growth driver
renal includ launch kaguya cycler japan theranova
dialyz us point technolog see
potenti poc transform pd therapi allow drive pd penetr
captur share significantli lower cost deliveri therapi
point poc
point poc
point poc first patient treat poc late
expect launch product alreadi plan second
gener version strateg horizon tradit periton dialysi requir
deliveri larg volum infus solut make logist difficult
especi patient infrastructur lack live small
dwell poc aim make pharmaceut industri grade steril infus
home take expertis make concentr glucos
electrolyt appli dose mix new pd cycler make
solut home allow deliveri prescript cycl
custom theoret improv qualiti life addit logist
success convert patient base poc shipment would
reduc milk-gallon size carton estim shipment would
reduc today convers us would
translat reduct truckload ship dialys infus around
countri think would drive save also remov
one primari barrier adopt pd
way background periton dialysi treatment kidney failur use
line abdomen peritoneum filter blood insid bodi cathet
place belli dialysi solut salt water addit flow
bag cathet abdomen solut contain sugar call
dextros compound call icodextrin miner pull wast extra
initi coverag novemb
fluid blood abdomen differ solut differ strength
dextros icodextrin solut insid abdomen absorb
wast extra fluid bodi hour solut wast
drain belli empti bag dispos
toilet tub need repeat per day fresh solut
process known exchang exchang done day
night use machin pump fluid call cycler
continu ambulatori periton dialysi capd doesnt use machin
involv exchang hand usual day capd solut
kept abdomen hour dwell time need
chang least per day exchang exchang take
minut done read talk watch tv sleep
autom periton dialysi machin exchang sleep
machin call cycler fill empti abdomen fluid per
night patient also typic start day fresh solut may keep
day exchang afternoon manual
dialysi solut come liter bag depend
person amount volum number bag per night differ
rememb physic water weight lb take cubic
decimetr cm cm cm weigh larger
gallon milk typic patient would receiv deliveri fluid
case weigh pound averag
typic deliv day order deliveri cycl
take space approxim make challeng store small
apart given size deliveri someon typic need home
receiv sign heavi awkward solut make
travel difficult patient histor ship fluid suppli
new cycler also import strategi especi kaguya japan
today penetr pd japan vs us us
canada europ good success amia us/can claria
eur cycler help streamlin patient therapi also connect
provid sharesourc platform notabl pd therapi still
dropout rate everi patient keep therapi year add
signific dollar bottom line note may patient
treat amia
drug like largest area expans
particip global non-or gener pharma market
grow includ sub-categori gener inject grow
drug compound inhal anesthesia declin
posit asept premix drug drug compound
market serv inhal anesthesia overal market growth
current exposur slower growth inhal
anesthesia market wamgr current
given intern plan acquisit partnership space abl
shift wamgr faster grow inject space estim
pharma busi chang busi term size
scale scope next three year invest heavili area
highlight new product revenu area
initi coverag novemb
busi market dynam inject favour given
market remain tight product shortag list
brand inject patent expir us next year hospit
use gener due cost pressur
gener inject busi major
differenti formul deliveri platform broadli work
cardiovascular anti-infect
expect address market doubl molecul
expans take molecul today expand
registr current put perspect
molecul make market today defin leader
space molecul averag look intern
develop partnership busi develop opportun reach
optim portfolio size lrp
doubl
size baxter
launch premix drug differenti platform key
strategi go market way help acceler penetr faster
reach peak sale faster compar launch compet
includ asept premix inhal product pre-filled syring drug
initi coverag novemb
termin steril multipl platform compani intern capabl
fill/finish manufactur plant small larg molecul tri
build capabl broadli partnership specif segment
target exist gener molecul also one come patent
specif target molecul could potenti get market earlier
formul technolog compet look
complex molecul lead supplier iv inject look
select biosimilar like oncolog support care
galaxi technolog use asept fill pre-mix contain steril
molecul termin steril molecul
termin steril break make effect
take put asept fill premix bag
administ patient tradit product would need
compound admix abl administ patient mani step
need take drug put final form dose
administ ready-to-us contain pre-mix bag provid simpli
take bag hang pole infus manipul need
take place dissolv lyophil drug inject bag reduc
chanc error lower risk infect reduc touchpoint
pharmaci bedsid increas effici hospit
scinopharm form partnership scinopharm allow produc
molecul scinopharm respons make activ pharmaceut
ingredi api opportun partner molecul
futur scinopharm world leader api manufactur send api
plant hall germani deep compet cytotox
abl fill/finish
cyclophosphamid exampl drug difficult make
challeng may creat barrier entri help retain exclus reduc
pool competitor drug allow take share
typic better price one competitor market cyclo
anoth potenti come abl hold share
would expect
initi coverag novemb
 balanc sheet discount current
current debt expect cash
gener next three year manag comment
sever issu behind compani time increas busi
develop follow bumpi increas share
repurchas author total look forward
expect manag team good track record add
growth margin accret deal could bump overal
target reward multipl
current price estim could buy back share base
without lever ad leverag estim could comfort
deal comment past suggest
market cap assum msd accret year dd accret year
larg deal could impli type valu creation stock look
anoth way use capac today purchas larg deal
high teen ebitda multipl could add revenu
assum someth accret margin assum asset grew
vs would add bp growth multipl
equal today
consensu expect aggress capit alloc
think lack deal flow surpris investor like
view hang view smart growth margin
accret deal would view posit potenti help share
re-rat
improv dramat under-lev
activ bus-dev due deal
increas repurchas stock sale
initi coverag novemb
improv dramat under-
lrp call oper margin
improv capx ration
improv work capit combin think could result
publicli state
would will deal size market cap
although prefer tuck in recent relax stanc
say could bigger deal right return
figur expect reach
activ bus-dev due deal
investor focus deal given compani strong balanc sheet
comment focus area given ceo almeida
track record covidien cfo jay saccaro financi disciplin anticip
deal done strongli root gener posit return covidien
deal tuck-in modest size deal compani use string
pearl approach upshift portfolio higher growth margin
adjac think kind approach could make good sens
seen sign move way deal manag
done date pharma biosurgeri
gener speak target leverag level net debt/ebitda
invest grade rate given balanc sheet fulli un-lev
gener strong free cash flow still give wide rang possibl
term bd perspect ceo almeida note
join compani lot thing fix right time
deal howev right strategi proven leader
organ confid execut deal
note time realli get go issu behind
initi coverag novemb
figur capac larg deal
notabl longer rang growth target includ anyth
busi develop first employ strateg criteria gener
look target accret wamgr
dilut gross margin potenti bd add top line
growth although note take lot capit deploy move top
line current environ valuat high note
bd move need one clear strateg opportun
current strateg bet includ invest disrupt renal model digit
critic care/extracorpor therapi infect control special
monitoricing/piva beyond analyst day laid potenti
opportun busi develop licens specif note three
area adjac ripe opportun target surgic specialti
gener inject local/region opportun four area expans
decis support new surgic special two transform area
chronic kidney diseas manag target biosimilar
beyond rigor financi criteria evalu deal first
look thing accret top bottom line evalu
intern rate return program expect program
deliv double-digit intern rate return life keep hurdl
high allow suffici margin safeti compani wacc make
invest decis critic import metric look
depend type deal
initi coverag novemb
increas repurchas stock sale
repurchas made base intrins valu model dcf look
year cash flow project plu perpetu rate assum share
repurchas off-set dilut mean next year
improv made cash flow substanti amount cash build could
cours busi continu increas dividend annual buy
back share essenti keep share flat call know
revenu miss share react neg manag highlight
could time look buy back share subsequ board
approv increas share repurchas author
author avail date
cash end share high
could buy back share base like could
see step higher level repurchas average/issu
share count could go forecast buy-back next
year share count come net cours year due
time buy-back off-set option issuanc add penni
ep
make improv target dividend increas
time expect pay-out ratio done target
dividend increas today pay dividend
annual repres given earn grow quickli
prioriti capit alloc share repurchas
take time get
initi coverag novemb
 overachiev margin target
possibl help new product busi develop stand
rang look doabl us model om near high end
forecast rang
look histori significantli outperform initi target
margin reach margin expect
rang expand margin becom core
compet implant chang cultur around cost
portfolio manag next leg forward execut portfolio
manag plan could drive gm expans
top cost cut program
implement drive anoth notabl new product forecast
risk adjust plan includ busi develop
out-performance new product growth expect accret
deal could sourc upsid given one unlev
balanc sheet group
consensu model oper margin give reason
full credit margin expans plan upsid
includ gm expans oper
expens leverag level
histori guid
initi coverag novemb
includ gm expans
oper expens leverag
expect bp margin expans mix gross
margin improv sg oper leverag gross margin
expans depend heavili cadenc success new product
launch also effici manufactur organ new product
launch carri higher margin corpor averag
within busi mix shift posit price also headwind
cyclophosphamid brevibloc
figur target om
oper expens continu work transform effort
get gener leverag grow top line msd rang
busi transform offic run program cost take-out
target anoth commit process lrp
overal plan includ gross margin expans oper margin
improv cost cut approach rais margin
post spin bp expect
figur om improv includ mix gm expans oper
initi coverag novemb
success sinc spin reduc cost oper
effort gain expect occur four key initi zero-
base organ zero-bas spend portfolio manag
rightsiz organ reduc layer manag
simplifi report structur time success employ
zero base budget cost assess elimin wast addit
mix work optim manufactur footprint oper
suppli chain network lower cost final central
streamlin support function gain effici effort expect
drive cumul save versu
figur initi drive cumul save vs
process develop long rang plan forecast number
compani high likelihood achiev beat given predict
busi increas abil drive margin improv improv
therefor rang outcom less year ago
initi coverag novemb
histori guid
look margin goal sinc spin expect margin
steadili risen given strong execut portfolio mix chang cost control
expect good oper potenti higher margin
product bd lead upsid
initi coverag novemb
growth could see
stabl base busi
new product
street give credit
margin expans doubt
abil grow
better execut pipelin bd
could chang
consensu slightli lower model rev ep
pt base ep share trade
past year trade close year multipl
low due broader market pullback well weaker expect
due tough comp look larg cap med-tech compani grow
revenu msd rang multipl go low rang ep
growth basi forecast grow low comp group
multipl suggest go mid
model organ revenu growth report growth
versu lrp guidanc organ growth
mm consensu revenu ep estim
slightli ahead consensu essenti anticip higher revenu growth
think continu invest behind growth opportun sg
estim consensu
initi coverag novemb
dcf analysi multipl examin consensu analysi
show premium valuat room upsid
trade ep year trough turn
year averag share de-rat driven miss result
well broader market declin current premium
versu three year averag see continu headroom
multipl versu high qualiti peer low
figur pe year low
pe rel
average rel
similarli trade ntm ebitda versu three year averag
min/max
ev/ebitda rel
average rel
initi coverag novemb
view deserv premium mani larg cap name due
rel stabl histori revenu growth larg potenti margin expans
show trade essenti in-lin broader larg cap
med-tech comp group pe basi
figur compar larg cap med-tech name
note ratio base consensu number factset price
initi coverag novemb
note ratio base consensu number factset price
initi coverag novemb
use linear regress growth versu multipl med-tech space
see trade slightli trend line deliv rel
consist top line grown signific room margin expans
give best ep growth prospect space
show pe regress revenu growth us
larg cap name slightli line regress
figur higher qualiti growth margin expans give premium valuat
compani report ub estim
initi coverag novemb
regress ev/ebitda versu growth
experi signific ebitda growth believ visibl
margin expans deserv least par multipl premium
expect compani show strongest margin expans
therefor ebitda growth group next two year regress
multipl versu expect ebitda growth also show amongst
cheapest stock use metric well regress line
figur normal ebitda growth near high end group
initi coverag novemb
dcf impli signific upsid base
dcf valu share base case wacc
termin margin reach versu goal
use year explicit forecast dcf intermedi forecast
beyond
use cost capit appli appropri cost equiti use
year risk free rate termin growth in-lin expect
compound-annual-growth-rate medicar age patient global
sale
sale
portion cf
tv
initi coverag novemb
upsid downsid
upsid upsid case assum organ growth
driven broad base product driver includ sever key new product
upsid deal predic stabl global market price
trend upsid case grow ebit margin bp
higher growth given high line leverag forecast mid
teen ep growth period
base base case assum organ growth
driven broad base product driver includ sever key new product
predic stabl global market price trend anticip
grow ebit margin bp digest deal invest
numer growth opportun given high line leverag
forecast low ep growth period
downsid downsid case assum organ growth
new product growth drag tough comp
segment scenario would includ modest soften global market
price trend condit anticip grow ebit
margin bp digest deal invest
numer growth opportun given modest line leverag
forecast hsd ep growth period
initi coverag novemb
provid broad portfolio essenti
healthcar product across portfolio includ acut
chronic dialysi therapi steril intraven iv
solut infus system devic parenter nutrit
pharmaceut surgic hemostat sealant
product compani six busi segment renal
sale acut therapi medic
advanc surgeri baxter headquart
encourag sector fundament includ
renaiss big new product driver push innovation-
led growth drumbeat steadi volum increas
popul age emerg market
earli inning util time med-tech
risk rel contain price trend larg
stabl low cost implant find littl traction area
physician prefer med-tech also view favour
polit part solut term abil
improv healthcar outcom lower cost
exposur leadership broad categori medic
suppli provid stabl top line growth also best
class execut margin expans
revenu region
revenu product segment
initi coverag novemb
profit tax
profit tax
equival
invest asset
trade payabl st liabil
net incom pref div
net chang work capit
chang debt pref share
flow inc/ dec cash
balanc sheet inc/ dec cash
compani account ub estim ub metric use report figur adjust ub ep ub dilut calcul use ub net incom ad back depreci
initi coverag novemb
buy minor
revenu divis us
ebit ub divis us
compani account ub estim ub metric use report figur adjust ub analyst
initi coverag novemb
initi coverag novemb
valuat method risk statement
price target base ep risk includ
slowdown hospit capit spend increas competit
hospit suppli compani competit entrant differenti product
delay key product approv reject regulatori bodi inabl
deliv msd top line growth meet consensu expect top line
miss guidanc consensu bottom line margin expans
slower expect
initi coverag novemb
